India Globalization Capital, Inc.  

(Public, NYSEMKT:IGC)   Watch this stock  
Find more results for NYSEAMEX:IGC
0.370
-0.015 (-3.87%)
Real-time:   12:05PM EDT
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.37 - 0.40
52 week 0.19 - 0.80
Open 0.40
Vol / Avg. 69,475.00/269,903.00
Mkt cap 10.15M
P/E     -
Div/yield     -
EPS -0.08
Shares 27.43M
Beta 2.43
Inst. own 2%
Nov 20, 2017
Q2 2018 India Globalization Capital Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 21, 2017
Q1 2018 India Globalization Capital Inc Earnings Release
Jul 14, 2017
Q4 2017 India Globalization Capital Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin -817.04% -319.25%
Operating margin -748.67% -353.98%
EBITD margin - -285.53%
Return on average assets -16.74% -12.29%
Return on average equity -25.75% -17.92%
Employees 31 -
CDP Score - -

Address

4336 Montgomery Ave
BETHESDA, MD 20814-4443
United States - Map
+1-301-9830998 (Phone)
+1-240-4650273 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

India Globalization Capital, Inc. develops intellectual property for the treatment of life altering or life threatening conditions, through its research on phytocannabinoid-based therapies, in the United States. The Company also builds farming facilities for leasing. In Malaysia, the Company develops and manages residential and commercial real estate. In India, it leases heavy equipment. It is also focused on developing, testing and patenting phytocannabinoid-based pharmaceutical therapies and becoming a specialty pharmaceutical provider of phytocannabinoid-based pharmaceutical and nutraceutical products. It is developing a product portfolio of phytocannabinoid-based therapies for indications, including neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis. In Malaysia, the Company’s subsidiary, Cabaran Ultima Sdn. Bhd., is focused on building a five-star hotel, Genting highlands.

Officers and directors

Richard K. Prins Chairman of the Board of Directors
Age: 58
Bio & Compensation  - Reuters
Ram Mukunda President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John Cherin Chief Financial Officer, Principal Accounting Officer, Treasurer
Age: 74
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Claudia Grimaldi General Manager, Director - Cabaran Ultima
Bio & Compensation  - Reuters
Sudhakar V. Shenoy Independent Director
Age: 68
Bio & Compensation  - Reuters